Talazoparib
- Generic Name
- Talazoparib
- Brand Names
- Talzenna
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14F2N6O
- CAS Number
- 1207456-01-6
- Unique Ingredient Identifier
- 9QHX048FRV
- Background
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
...
- Indication
Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
...
- Associated Conditions
- HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC), Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Associated Therapies
- -
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 431
- Registration Number
- NCT01945775
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT01286987
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Santa Monica - UCLA Medical Center & Orthopaedic Hospital, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.